Skip to main content

Table 1 Results of CIITA genotyping in MG patients and controls.

From: Lack of association of the CIITA-168A→G promoter SNP with myasthenia gravis and its role in autoimmunity

MG patients

AA

AG

GG

A

G

MAF

p-vala

Significance threshold

OR (95% C.I.)

p-val referenceb

All patients (n = 446)

260

159

27

679

213

0.239

0.092

0.05

0.86 (0.73-1.02)

0.154

Age of onset <40 (n = 226)

127

80

19

334

118

0.261

0.810

6.25 × 10 -3

1.03 (0.82-1.28)

0.032

Age of onset >50 (n = 175)

110

59

6

279

71

0.203

0.010

6.25 × 10 -3

1.43 (1.09-1.87)

0.559

Ocular (n = 42)

29

12

1

70

14

0.167

0.040

6.25 × 10 -3

0.55 (0.31-0.98)

0.274

Generalized (n = 404)

231

147

26

609

199

0.246

0.240

6.25 × 10 -3

0.90 (0.76-1.07)

0.068

Not operated (n = 171)

103

58

10

264

78

0.228

0.124

6.25 × 10 -3

0.81 (0.63-1.06)

0.619

Normal thymus (n = 60)

35

25

0

95

25

0.208

0.156

6.25 × 10 -3

0.72 (0.46-1.13)

0.833

Thymic hyperplasia (n = 157)

87

59

11

233

81

0.258

0.747

6.25 × 10 -3

0.96 (0.74-1.25)

0.090

Thymoma (n = 58)

35

17

6

87

29

0.250

0.695

6.25 × 10 -3

0.92 (0.60-1.41)

0.389

aControls (n = 1866)

1015

708

143

2738

994

0.266

    

bControls (n = 1599)

989

528

82

2506

692

0.216

    
  1. Genotypes, frequencies of A and G alleles as well as the minor allele frequency (MAF) for MG patients and various subgroups of patients compared to the measured controlsa and the controls from Swanberg et. al.b [4]. The significance threshold applies a Bonferroni correction for eight tests on subsequent subgroup classifications.